12:00 AM
 | 
Feb 04, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/1 cls
Achillion (NASDAQ:ACHN) JMP Securities Liisa Bayko New Market perform 29% $5.38
Bayko expects 24-week data soon from a Phase II trial of elvucitabine to treat HIV infection, which she said will shed light on the "partnerability" of the nucleoside reverse transcriptase inhibitor (NRTI). Bayko also expects an IND submission for ACH-1095 to treat HCV infection in 2H08. The non-structural protein 4A (NS4A) antagonist is partnered with Gilead (NASDAQ:GILD).
Acorda (NASDAQ:ACOR) Banc of America Securities William Ho Price target Buy 23% $26.86
Fortis Patrick Moriarty Price target Buy
Lazard Joel Sendek Price target Buy
Ho raised his target to $33 from $26 after Acorda announced that the electrocardiographic QT interval with Fampridine-SR treatment was not significantly different than placebo. The sustained-release formulation of 4-aminopyridine (4-AP) is in the Phase III MS-F204 trial to treat multiple sclerosis (MS). The trial is expected to complete next quarter. Ho anticipates an NDA submission in early 2009 (see B13).
Moriarty raised his target to $37 from $33 based on the positive results of the QT study. He expects Acorda to submit an NDA for Fampridine-SR for MS in 1Q09 with approval and launch in 4Q09.
Sendek raised his target to $35 from $28 on the...

Read the full 1265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >